The Indiana Pacers announced guard Caris LeVert underwent successful kidney surgery on Monday and is expected to make a full recovery.
LeVert's surgery treated a renal cell carcinoma — a type of cancer — of his left kidney. While he remains out indefinitely, LeVert will not require further treatment.
This is tremendous news for LeVert in what began as a bit of a scary situation.
Indiana acquired Caris LeVert as part of the revised four-team deal that sent James Harden to the Brooklyn Nets. The promising combo guard had averaged 18.5 points, 6.0 assists and 4.3 rebounds through his first 12 games with the Nets, and immediately figured into the Pacers' backcourt picture. LeVert also offered a contrast to Victor Oladipo in that he is under contract through the 2022-23 season.
But further medical testing revealed a small mass on LeVert's kidney. The Pacers announced he would be out indefinitely and seek treatment, but there was some uncertainty as to the severity of the issue.
Fortunately, it appears Caris LeVert will have every opportunity to return to the floor once he makes the expected recovery.
Indiana was an interesting player in the Harden deal. The Pacers got out from under Oladipo's expiring contract, and in the process acquired a player in LeVert who does many of the same things offensively.
LeVert could be an anchor for a backcourt also consisting of Malcolm Brogdon and Aaron Holiday, among others. The Pacers are building something for the future and hope LeVert can be part of numerous successes.
First and foremost, however, the basketball community will rejoice at the news of Caris LeVert's successful surgery and expected recovery.
Follow Us
Subscribe